Comprehensive analysis of microRNAs modulated by histone deacetylase inhibitors identifies microRNA-7-5p with anti-myeloma effect.
Multiple myeloma
PSME3
Panobinostat
miR-7
microRNA
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
02 Jul 2024
02 Jul 2024
Historique:
received:
08
02
2024
accepted:
26
06
2024
revised:
09
06
2024
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
2
7
2024
Statut:
aheadofprint
Résumé
Basic research to expand treatment options for multiple myeloma is greatly needed due to the refractory nature of the disease. Histone deacetylase (HDAC) inhibitors, which are epigenetic regulators, are attractive but have limited applications. MicroRNAs (miRNAs), which are also epigenetic regulators, are important molecules that may lead to future therapeutic breakthroughs. In this study, we comprehensively searched for miRNAs that are altered by HDAC inhibitors in myeloma cells. We identified miR-7-5p (miR-7) as a miRNA downregulated by HDAC inhibitors. Transfection of myeloma cell lines with miR-7 suppressed cell proliferation, induced apoptosis, and enhanced the effects of the HDAC inhibitor panobinostat. Expression of miR-7 was downregulated by c-Myc inhibition, but upregulated by bortezomib. Comprehensive examination of miR-7 targets revealed four candidates: SLC6A9, LRRC59, EXOSC2, and PSME3. Among these, we focused on PSME3, an oncogene involved in proteasome capacity in myeloma cells. PSME3 knockdown increases myeloma cell death and panobinostat sensitivity. In conclusion, miR-7, which is downregulated by HDAC inhibitors, is a tumor suppressor that targets PSME3. This miR-7 downregulation may be involved in HDAC inhibitor resistance. In addition, combinations of anti-myeloma drugs that complement changes in miRNA expression should be considered.
Identifiants
pubmed: 38954186
doi: 10.1007/s12185-024-03812-1
pii: 10.1007/s12185-024-03812-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 17K16179
Informations de copyright
© 2024. Japanese Society of Hematology.
Références
van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410–27.
pubmed: 33516340
doi: 10.1016/S0140-6736(21)00135-5
Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol. 2022;115:762–77.
pubmed: 35534749
pmcid: 9160142
doi: 10.1007/s12185-022-03353-5
Wolffe AP. Histone deacetylase: a regulator of transcription. Science. 1996;272:371–2.
pubmed: 8602525
doi: 10.1126/science.272.5260.371
Smith EM, Boyd K, Davies FE. The potential role of epigenetic therapy in multiple myeloma. Br J Haematol. 2010;148:702–13.
pubmed: 19912222
doi: 10.1111/j.1365-2141.2009.07976.x
Berdeja JG, Laubach JP, Richter J, et al. Panobinostat from bench to bedside: rethinking the treatment paradigm for multiple myeloma. Clin Lymphoma Myeloma Leuk. 2021;21:752–65.
pubmed: 34340951
doi: 10.1016/j.clml.2021.06.020
Harada T, Hideshima T, Anderson KC. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol. 2016;104:300–9.
pubmed: 27099225
doi: 10.1007/s12185-016-2008-0
Ohguchi H, Hideshima T, Anderson KC. The biological significance of histone modifiers in multiple myeloma: clinical applications. Blood Cancer J. 2018;8:83.
pubmed: 30190472
pmcid: 6127133
doi: 10.1038/s41408-018-0119-y
Imai Y, Hirano M, Kobayashi M, Futami M, Tojo A. HDAC inhibitors exert anti-myeloma effects through multiple modes of action. Cancers (Basel). 2019;11:475.
pubmed: 30987296
doi: 10.3390/cancers11040475
San-Miguel JF, Richardson PG, Günther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31:3696–703.
pubmed: 24019544
doi: 10.1200/JCO.2012.46.7068
Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122:2331–7.
pubmed: 23950178
doi: 10.1182/blood-2013-01-481325
San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–206.
pubmed: 25242045
doi: 10.1016/S1470-2045(14)70440-1
Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31–9.
pubmed: 16960145
pmcid: 1785068
doi: 10.1182/blood-2006-06-025999
Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485–91.
pubmed: 20697094
doi: 10.1200/JCO.2010.28.9066
Utsunomiya A, Izutsu K, Jo T, Yoshida S, et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: phase IIb results. Cancer Sci. 2022;113:2778–87.
pubmed: 35579212
pmcid: 9357668
doi: 10.1111/cas.15431
Rai S, Kim WS, Ando K, et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2023;108:811–21.
pubmed: 36200417
doi: 10.3324/haematol.2022.280996
Abe F, Kitadate A, Ikeda S, et al. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. Oncotarget. 2017;8:7572–85.
pubmed: 27935859
doi: 10.18632/oncotarget.13810
Bartel DP. Metazoan MicroRNAs. Cell. 2018;173:20–51.
pubmed: 29570994
pmcid: 6091663
doi: 10.1016/j.cell.2018.03.006
Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–22.
pubmed: 28209991
doi: 10.1038/nrd.2016.246
Amodio N, Stamato MA, Gullà AM, et al. Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 2016;15:1364–75.
pubmed: 27196750
doi: 10.1158/1535-7163.MCT-15-0985
Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008;105:12885–90.
pubmed: 18728182
pmcid: 2529070
doi: 10.1073/pnas.0806202105
Chi J, Ballabio E, Chen XH, et al. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct. 2011;6:23.
pubmed: 21592325
pmcid: 3120802
doi: 10.1186/1745-6150-6-23
Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40:43–50.
pubmed: 18066065
doi: 10.1038/ng.2007.30
Chou YT, Lin HH, Lien YC, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res. 2010;70:8822–31.
pubmed: 20978205
doi: 10.1158/0008-5472.CAN-10-0638
Yu Z, Wei X, Liu L, et al. Indirubin-3’-monoxime acts as proteasome inhibitor: therapeutic application in multiple myeloma. EBioMedicine. 2022;78: 103950.
pubmed: 35344764
pmcid: 8958548
doi: 10.1016/j.ebiom.2022.103950
Sanchez N, Gallagher M, Lao N, et al. MiR-7 triggers cell cycle arrest at the G1/S transition by targeting multiple genes including Skp2 and Psme3. PLoS One. 2013;8: e65671.
pubmed: 23762407
pmcid: 3675065
doi: 10.1371/journal.pone.0065671
Xiong S, Zheng Y, Jiang P, et al. PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer. Br J Cancer. 2014;110:353–62.
pubmed: 24281003
doi: 10.1038/bjc.2013.728
Tang S, Ma D, Cheng B, et al. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma. Exp Cell Res. 2018;363:196–207.
pubmed: 29317217
doi: 10.1016/j.yexcr.2018.01.005
Abe K, Ikeda S, Nara M, et al. Hypoxia-induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase-1 in multiple myeloma. Cancer Med. 2023;12:9709–22.
pubmed: 36775962
pmcid: 10166934
doi: 10.1002/cam4.5679
Handa H, Murakami Y, Ishihara R, Kimura-Masuda K, Masuda Y. The role and function of microRNA in the pathogenesis of multiple myeloma. Cancers (Basel). 2019;11:1738.
pubmed: 31698726
doi: 10.3390/cancers11111738
Zhao J, Tao Y, Zhou Y, et al. MicroRNA-7: a promising new target in cancer therapy. Cancer Cell Int. 2015;15:103.
pubmed: 26516313
pmcid: 4625531
doi: 10.1186/s12935-015-0259-0
Okuda H, Xing F, Pandey PR, et al. miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res. 2013;73:1434–44.
pubmed: 23384942
pmcid: 3576138
doi: 10.1158/0008-5472.CAN-12-2037
Suto T, Yokobori T, Yajima R, et al. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis. 2015;36:338–45.
pubmed: 25503932
doi: 10.1093/carcin/bgu242
Ikeda S, Kitadate A, Abe F, et al. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma. Cancer Sci. 2017;108:641–52.
pubmed: 28164410
pmcid: 5406542
doi: 10.1111/cas.13183
Wong WJ, Qiu B, Nakazawa MS, Qing G, Simon MC. MYC degradation under low O2 tension promotes survival by evading hypoxia-induced cell death. Mol Cell Biol. 2013;33:3494–504.
pubmed: 23816886
pmcid: 3753854
doi: 10.1128/MCB.00853-12
Dang CV, O’donnell KA, Juopperi T. The great MYC escape in tumorigenesis. Cancer Cell. 2005;8:177–8.
pubmed: 16169462
doi: 10.1016/j.ccr.2005.08.005
Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene. 2008;27:6462–72.
pubmed: 18955973
doi: 10.1038/onc.2008.312
Schmidt S, et al. A MYC-GCN2-eIF2α negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer. Nat Cell Biol. 2019;21:1413–24.
pubmed: 31685988
pmcid: 6927814
doi: 10.1038/s41556-019-0408-0
Liu S, Zang H, Zheng H, et al. miR-4634 augments the anti-tumor effects of RAD001 and associates well with clinical prognosis of non-small cell lung cancer. Sci Rep. 2020;10:13079.
pubmed: 32753611
pmcid: 7403585
doi: 10.1038/s41598-020-70157-0
Liu S, Wang W, Ning Y, et al. Exosome-mediated miR-7-5p delivery enhances the anticancer effect of Everolimus via blocking MNK/eIF4E axis in non-small cell lung cancer. Cell Death Dis. 2022;13:129.
pubmed: 35136028
pmcid: 8827062
doi: 10.1038/s41419-022-04565-7
Maruhashi T, Miki H, Sogabe K, et al. Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib. Int J Hematol. 2024;119:291–302.
pubmed: 38252236
doi: 10.1007/s12185-023-03706-8
Sogabe K, Nakamura S, Higa Y, et al. Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors. Int J Hematol. 2024;119:303–15.
pubmed: 38245883
doi: 10.1007/s12185-023-03705-9
Guo J, Hao J, Jiang H, et al. Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis. Cancer Lett. 2017;386:161–7.
pubmed: 27756569
doi: 10.1016/j.canlet.2016.08.018
Boulpicante M, Darrigrand R, Pierson A, et al. Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3. Oncoimmunology. 2020;9:1761205.
pubmed: 32923122
pmcid: 7458623
doi: 10.1080/2162402X.2020.1761205
Yi Z, Yang D, Liao X, et al. PSME3 induces epithelial-mesenchymal transition with inducing the expression of CSC markers and immunosuppression in breast cancer. Exp Cell Res. 2017;358:87–93.
pubmed: 28529105
doi: 10.1016/j.yexcr.2017.05.017